From: Prognosis prediction in esophageal signet-ring-cell carcinoma: a competing risk analysis
Variables | Total (n = 564) | Training (n = 282) | Validation (n = 282) | P value | |||
---|---|---|---|---|---|---|---|
No | % | No | % | No | % | ||
Age at Diagnosis | Â | Â | Â | Â | Â | Â | 0.063 |
 Mean ± SD | 66.64 ± 10.9 |  | 65.96 ± 11.09 |  | 67.31 ± 10.69 |  | 0.142 |
 Age <  = 65 | 261 | 46 | 142 | 50 | 119 | 42 |  |
 Age > 65 | 303 | 54 | 140 | 50 | 163 | 58 |  |
Sex | Â | Â | Â | Â | Â | Â | 0.523 |
 Female | 70 | 12 | 38 | 13 | 32 | 11 |  |
 Male | 494 | 88 | 244 | 87 | 250 | 89 |  |
Race | Â | Â | Â | Â | Â | Â | 1 |
 Others | 41 | 7 | 20 | 7 | 21 | 7 |  |
 White | 523 | 93 | 262 | 93 | 261 | 93 |  |
Marital Status | Â | Â | Â | Â | Â | Â | 0.892 |
 Divorced/Separated | 55 | 10 | 29 | 10 | 26 | 9 |  |
 Married | 343 | 61 | 167 | 59 | 176 | 62 |  |
 Single/Unmarried | 93 | 16 | 48 | 17 | 45 | 16 |  |
 Widowed/Others | 73 | 13 | 38 | 13 | 35 | 12 |  |
History of Malignancy | Â | Â | Â | Â | Â | Â | 1 |
 Newly | 543 | 96 | 272 | 96 | 271 | 96 |  |
 Previously | 21 | 4 | 10 | 4 | 11 | 4 |  |
Primary Site | Â | Â | Â | Â | Â | Â | 0.507 |
 15-32 cm | 42 | 7 | 20 | 7 | 22 | 8 |  |
 33-40 cm | 468 | 83 | 231 | 82 | 237 | 84 |  |
 Others | 54 | 10 | 31 | 11 | 23 | 8 |  |
Grade | Â | Â | Â | Â | Â | Â | 0.979 |
 I-II | 25 | 4 | 13 | 5 | 12 | 4 |  |
 III-IV | 457 | 81 | 228 | 81 | 229 | 81 |  |
 Others | 82 | 15 | 41 | 15 | 41 | 15 |  |
AJCC Stage | Â | Â | Â | Â | Â | Â | 0.26 |
 I | 67 | 12 | 26 | 9 | 41 | 15 |  |
 II | 120 | 21 | 60 | 21 | 60 | 21 |  |
 III | 192 | 34 | 101 | 36 | 91 | 32 |  |
 IV | 185 | 33 | 95 | 34 | 90 | 32 |  |
Tumor Size | Â | Â | Â | Â | Â | Â | 0.114 |
 T1 | 133 | 24 | 56 | 20 | 77 | 27 |  |
 T2 | 59 | 10 | 26 | 9 | 33 | 12 |  |
 T3 | 243 | 43 | 127 | 45 | 116 | 41 |  |
 T4 | 74 | 13 | 44 | 16 | 30 | 11 |  |
 TX | 55 | 10 | 29 | 10 | 26 | 9 |  |
Node Status | Â | Â | Â | Â | Â | Â | 0.823 |
 N0 | 196 | 35 | 103 | 37 | 93 | 33 |  |
 N1 | 257 | 46 | 124 | 44 | 133 | 47 |  |
 N2 | 64 | 11 | 31 | 11 | 33 | 12 |  |
 N3/NX | 47 | 8 | 24 | 9 | 23 | 8 |  |
Regional Nodes Examined | Â | Â | Â | Â | Â | Â | 0.344 |
 0 | 415 | 74 | 204 | 72 | 211 | 75 |  |
 0–10 | 52 | 9 | 31 | 11 | 21 | 7 |  |
 11–60 | 97 | 17 | 47 | 17 | 50 | 18 |  |
Positive Lymph Nodes | Â | Â | Â | Â | Â | Â | 0.682 |
 0 | 485 | 86 | 240 | 85 | 245 | 87 |  |
 0–2 | 44 | 8 | 22 | 8 | 22 | 8 |  |
 3–35 | 35 | 6 | 20 | 7 | 15 | 5 |  |
Bone Metastases | Â | Â | Â | Â | Â | Â | 1 |
 NO/Unknown | 514 | 91 | 257 | 91 | 257 | 91 |  |
 YES | 50 | 9 | 25 | 9 | 25 | 9 |  |
Liver Metastases | Â | Â | Â | Â | Â | Â | 1 |
 NO/Unknown | 516 | 91 | 258 | 91 | 258 | 91 |  |
 YES | 48 | 9 | 24 | 9 | 24 | 9 |  |
Lung Metastases | Â | Â | Â | Â | Â | Â | 0.693 |
 NO/Unknown | 537 | 95 | 267 | 95 | 270 | 96 |  |
 YES | 27 | 5 | 15 | 5 | 12 | 4 |  |
Surgery | Â | Â | Â | Â | Â | Â | 0.855 |
 NO | 391 | 69 | 194 | 69 | 197 | 70 |  |
 YES | 173 | 31 | 88 | 31 | 85 | 30 |  |
Radiotherapy | Â | Â | Â | Â | Â | Â | 0.495 |
 NO | 424 | 75 | 208 | 74 | 216 | 77 |  |
 YES | 140 | 25 | 74 | 26 | 66 | 23 |  |
Chemotherapy | Â | Â | Â | Â | Â | Â | 0.213 |
 NO | 148 | 26 | 67 | 24 | 81 | 29 |  |
 YES | 416 | 74 | 215 | 76 | 201 | 71 |  |
Outcomes | Â | Â | Â | Â | Â | Â | 0.639 |
 Survival | 113 | 20 | 52 | 18 | 61 | 22 |  |
 Cancer-specific death | 355 | 63 | 181 | 64 | 174 | 62 |  |
 Other-cause death | 96 | 17 | 49 | 17 | 47 | 17 |  |